REG - Oxford Biomedica PLC - Grant of Options
04/10/2024 15:30
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241004:nRSD0535Ha&default-theme=true
RNS Number : 0535H Oxford Biomedica PLC 04 October 2024
Grant of options
Oxford, UK - 04 October 2024: Oxford Biomedica plc ("OXB" or the "Company";
LSE: OXB), a quality and innovation-led cell and gene therapy CDMO, today
announces that on 03 October 2024 nil-cost share options over ordinary shares
of 50 pence each in the Company were granted under the OXB 2024 Long Term
Incentive Plan ("LTIP").
2024 LTIP Awards
Name of individual Title Number of shares subject to the DBP/LTIP award prior to 2024 award Number of shares subject to the 2024 LTIP award Total shares over which options now held Percentage of current issued share capital under option
Frank Mathias Chief Executive Officer 323,178 257,113 580,291 0.55%
Lucinda Crabtree Chief Financial Officer - 170,113 170,113 0.16%
Sebastien Ribault Chief Business Officer 66,903 58,406 125,309 0.12%
Thierry Cournez Chief Operating Officer 66,437 51,570 118,007 0.11%
Lisa James Chief People Officer 99,989 40,464 140,453 0.13%
Kyriacos Mitrophanous Chief Innovation Officer 179,433 52,651 232,084 0.22%
Natalie Walter Group General Counsel and Company Secretary 152,818 49,169 201,987 0.19%
In line with best practice, the award granted to Frank Mathias was scaled back
from 200% of salary to 160% of salary, with the same proportionate scale back
applied to below board grantees. As a newly appointed Director, Lucinda
Crabtree's award was scaled back from 175% of salary to 157.5% of salary.
The Remuneration Committee has determined that EBITDA margin and revenue
growth are the key metrics aligned with the growth strategy. Therefore, for
this grant the performance conditions will be based on those metrics, weighted
40% EBITDA margin and 60% revenue growth, with no non-financial leading
performance indicators metrics. Performance in respect of each measure will be
assessed following the end of a three year performance period ending with
2026. Details of the targets for the EBITDA margin and revenue growth measures
are included in the 2023 Directors' Remuneration Report.
The awards will "vest" on 3 October 2027 to the extent determined by reference
to the assessment of the performance condition. The awards granted to Frank
Mathias and Lucinda Crabtree will only be "released" so that they can be
exercised following the end of a further two year holding period. The awards
granted to other participants will be released at vesting.
The Notification of Dealing Forms set out below are provided in accordance
with the requirements of the EU Market Abuse Regulation.
Notification of Dealing Form
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Frank Mathias
2. Reason for the notification
a) Position/status Chief Executive Officer
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive
Plan. No consideration was paid for the grant of awards.
c) Price(s) and volumes(s) 2024 LTIP Award
Price Volume
Nil 257,113
d) Aggregated information
- Aggregate volume Awards granted over 257,113 shares in total
- Price
N/A
e) Date of the transaction 2024-10-03
f) Place of the transaction Outside of trading venue
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 257,113 shares in total
N/A
e)
Date of the transaction
2024-10-03
f)
Place of the transaction
Outside of trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Lucinda Crabtree
2. Reason for the notification
a) Position/status Chief Financial Officer
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive
Plan. No consideration was paid for the grant of awards.
c) Price(s) and volumes(s) 2024 LTIP Award
Price Volume
Nil 170,113
d) Aggregated information
- Aggregate volume Awards granted over 170,113 shares in total
- Price
N/A
e) Date of the transaction 2024-10-03
f) Place of the transaction Outside of trading venue
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 170,113 shares in total
N/A
e)
Date of the transaction
2024-10-03
f)
Place of the transaction
Outside of trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Sebastien Ribault
2. Reason for the notification
a) Position/status Chief Business Officer
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive
Plan. No consideration was paid for the grant of awards.
c) Price(s) and volumes(s) 2024 LTIP Award
Price Volume
Nil 58,406
d) Aggregated information
- Aggregate volume Awards granted over 58,406 shares in total
- Price
N/A
e) Date of the transaction 2024-10-03
f) Place of the transaction Outside of trading venue
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 58,406 shares in total
N/A
e)
Date of the transaction
2024-10-03
f)
Place of the transaction
Outside of trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Thierry Cournez
2. Reason for the notification
a) Position/status Chief Operating Officer
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive
Plan. No consideration was paid for the grant of awards.
c) Price(s) and volumes(s) 2024 LTIP Award
Price Volume
Nil 51,570
d) Aggregated information
- Aggregate volume Awards granted over 51,570 shares in total
- Price
N/A
e) Date of the transaction 2024-10-03
f) Place of the transaction Outside of trading venue
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 51,570 shares in total
N/A
e)
Date of the transaction
2024-10-03
f)
Place of the transaction
Outside of trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Lisa James
2. Reason for the notification
a) Position/status Chief People Officer
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive
Plan. No consideration was paid for the grant of awards.
c) Price(s) and volumes(s) 2024 LTIP Award
Price Volume
Nil 40,464
d) Aggregated information
- Aggregate volume Awards granted over 40,464 shares in total
- Price
N/A
e) Date of the transaction 2024-10-03
f) Place of the transaction Outside of trading venue
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 40,464 shares in total
N/A
e)
Date of the transaction
2024-10-03
f)
Place of the transaction
Outside of trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Kyriacos Mitrophanous
2. Reason for the notification
a) Position/status Chief Innovation Officer
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive
Plan. No consideration was paid for the grant of awards.
c) Price(s) and volumes(s) 2024 LTIP Award
Price Volume
Nil 52,651
d) Aggregated information
- Aggregate volume Awards granted over 52,651 shares in total
- Price
N/A
e) Date of the transaction 2024-10-03
f) Place of the transaction Outside of trading venue
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 52,651 shares in total
N/A
e)
Date of the transaction
2024-10-03
f)
Place of the transaction
Outside of trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Natalie Walter
2. Reason for the notification
a) Position/status General Counsel
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive
Plan. No consideration was paid for the grant of awards.
c) Price(s) and volumes(s) 2024 LTIP Award
Price Volume
Nil 49,169
d) Aggregated information
- Aggregate volume Awards granted over 49,169 shares in total
- Price
N/A
e) Date of the transaction 2024-10-03
f) Place of the transaction Outside of trading venue
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 49,169 shares in total
N/A
e)
Date of the transaction
2024-10-03
f)
Place of the transaction
Outside of trading venue
-Ends-
Enquiries:
Oxford Biomedica plc:
Natalie Walter, Company Secretary Tel: +44 (0)1865 783 000
About OXB
OXB (LSE: OXB) is a quality and innovation-led contract development and
manufacturing organisation (CDMO) in cell and gene therapy with a mission to
enable its clients to deliver life changing therapies to patients around the
world.
One of the original pioneers in cell and gene therapy, OXB has more than 25
years of experience in viral vectors; the driving force behind the majority of
cell and gene therapies. OXB collaborates with some of the world's most
innovative pharmaceutical and biotechnology companies, providing viral vector
development and manufacturing expertise in lentivirus, adeno-associated virus
(AAV), adenovirus and other viral vector types. OXB's world-class capabilities
span from early stage development to commercialisation. These capabilities are
supported by robust quality-assurance systems, analytical methods and depth of
regulatory expertise.
OXB offers a vast number of unique technologies for viral vector
manufacturing, including a 4th generation lentiviral vector system (the
Tetravecta™ system), dual plasmid system for AAV production, suspension and
perfusion process using process enhancers and stable producer and packaging
cell lines.
OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has
bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon and
Strasbourg, France and near Boston, MA, US. Learn more at www.oxb.com
(http://www.oxb.com) , and follow us on LinkedIn
(https://www.linkedin.com/company/oxford-biomedica) and YouTube.
(https://www.youtube.com/oxfordbiomedica)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHZZMGGDDMGDZMRecent news on Oxford BioMedica
See all newsREG - Oxford Biomedica PLC - Total Voting Rights
AnnouncementREG - Oxford Biomedica PLC - Person Closely Associated Dealing
AnnouncementREG - Oxford Biomedica PLC - Holding(s) in Company
AnnouncementREG - Oxford Biomedica PLC - 2025 Annual General Meeting notification
AnnouncementREG - Oxford Biomedica PLC - Holding(s) in Company
Announcement